CompletedNCT01922258
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Medication studyAges 55–90Multiple countriesMental health
Understand this study
Who was this study for?
Listed age limits: 55 years to 90 years.
- Listed locations
- Imperial and 69 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: September 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 270
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Canada, ...
- Age range
- From 55 Years to 90 Years
- Official registry ID
- NCT01922258
- Official title
Show the full official title
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Flexible Dosing of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedImperial, United States · Lakewood, United States · Long Beach, United States
58 more locations
- Panorama City, United States
- Universal City, United States
- Denver, United States
- Bradenton, United States
- Miami, United States
- Orange City, United States
- Atlanta, United States
- Smyrna, United States
- Honolulu, United States
- Indianapolis, United States
- Quincy, United States
- South Dartmouth, United States
- Ann Arbor, United States
- Brooklyn, United States
- Buffalo, United States
- New Hyde Park, United States
- Charlotte, United States
- Raleigh, United States
- Austin, United States
- Dallas, United States
- Woodstock, United States
- Burgas, Bulgaria
- Kardzhali, Bulgaria
- Pazardzhik, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Veliko Tarnovo, Bulgaria
- Penticton, Canada
- Kentville, Canada
- Kuopio, Finland
- Turku, Finland
- Bourg-en-Bresse, France
- Douai, France
- Élancourt, France
- Limoges, France
- Nice, France
- Toulouse, France
- Tonnel’nyy, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Yekaterinburg, Russia
- Ljubljana, Slovenia
- Maribor, Slovenia
- Sempeter pri Gorici, Slovenia
- Donetsk, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kiev, Ukraine
- Lviv, Ukraine
- Poltava, Ukraine
- Simferopol, Ukraine
- Vinnytsia, Ukraine
- Crewe, United Kingdom
- Manchester, United Kingdom
- Margate, United Kingdom
- Torpoint, United Kingdom
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Brexpiprazole, OPC-34712.
Who was this study for?
Listed age limits: 55 years to 90 years.
Want to explore more studies?
Explore studiesRelated studies
A Phase 1, Open Label, Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Pimavanserin in Adolescents with Psychiatric Disorders
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation